Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

NCT01593670 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Decitabine
DRUG: Vorinostat
BIOLOGICAL: Interleukin-2
OTHER: Natural killer (NK) cells

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]